CervoMed (CRVO) vs Elicio Therapeutics (ELTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CervoMed (CRVO) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 63.1% versus a loss of 82.8%. Over five years, CRVO leads with a -90.9% price change compared with -97.9% for ELTX. CervoMed is the larger company by market cap ($49.6 million vs $47.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | ELTX |
|---|---|---|
| Share price | $3.28 | $1.81 |
| Market cap | $49.59M | $47.57M |
| 1-day change | +3.14% | -2.16% |
| YTD return | -58.48% | -77.26% |
| 1-year return | -63.15% | -82.79% |
| 5-year return | -90.89% | -97.92% |
| EPS (TTM) | $-3.21 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $16.00 |
| 52-week low | $2.13 | $1.71 |
| Distance from 52-week high | -67.20% | -88.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +369.51% | +655.25% |
| Average volume | 339.08K | 340.72K |
| Shares outstanding | 15.12M | 26.28M |
| Employees | 15 | 33 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVO has outperformed ELTX by 19.6 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Healthcare · Biotechnology · 15 employees
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Healthcare · Biotechnology · 33 employees
CRVO vs ELTX FAQ
Which is bigger, CervoMed or Elicio Therapeutics?
CervoMed (CRVO) is larger, with a market capitalization of $49.59M compared with $47.57M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, CRVO or ELTX?
CRVO returned -63.15% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Elicio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.